PE20151090A1 - Lactamas fusionadas de arilo y heteroarilo - Google Patents
Lactamas fusionadas de arilo y heteroariloInfo
- Publication number
- PE20151090A1 PE20151090A1 PE2015001044A PE2015001044A PE20151090A1 PE 20151090 A1 PE20151090 A1 PE 20151090A1 PE 2015001044 A PE2015001044 A PE 2015001044A PE 2015001044 A PE2015001044 A PE 2015001044A PE 20151090 A1 PE20151090 A1 PE 20151090A1
- Authority
- PE
- Peru
- Prior art keywords
- heteroaryl
- aryl
- fused lactams
- compounds
- lactams
- Prior art date
Links
- 150000003951 lactams Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 abstract 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta invencion se refiere a compuestos de la formula general (I) en la cual R1, R2, U, V, L, M, R5, m, X, Y y Z son como aqui se definieron, y las sales farmaceuticamente aceptables del mismo, a composiciones farmaceuticas que comprenden dichos compuestos y sales; ademas son moduladores de la actividad de EZH2, por lo que pueden ser utiles para el tratamiento de crecimiento celular anormal, que incluye cancer
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740596P | 2012-12-21 | 2012-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151090A1 true PE20151090A1 (es) | 2015-08-07 |
Family
ID=49917684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015001044A PE20151090A1 (es) | 2012-12-21 | 2013-12-05 | Lactamas fusionadas de arilo y heteroarilo |
Country Status (46)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| EP3421482A1 (en) | 2012-12-21 | 2019-01-02 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2015023915A1 (en) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2015193768A1 (en) * | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
| BR112016029612B1 (pt) | 2014-06-17 | 2021-01-19 | Pfizer Inc. | compostos de di-hidroisoquinolinona substituídos |
| CN107148419A (zh) * | 2014-10-28 | 2017-09-08 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Zeste增强子同源物2抑制剂 |
| AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| WO2016101956A2 (en) | 2014-12-23 | 2016-06-30 | University Of Copenhagen | Treatment of cancer by inhibiting ezh2 activity |
| GEP20197032B (en) * | 2015-03-27 | 2019-10-25 | Participations Ag Syngenta | Microbiocidal heterobicyclic derivatives |
| UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| JP6828229B2 (ja) | 2015-11-19 | 2021-02-10 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ベンゾフラン誘導体、その製造方法および医薬におけるその使用 |
| EP3452483B1 (en) | 2016-05-05 | 2020-04-01 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
| US10457640B2 (en) | 2016-10-19 | 2019-10-29 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of EZH2 |
| US20200262813A1 (en) * | 2016-11-11 | 2020-08-20 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 1,5,7-trisubstituted isoquinoline derivatives, preparation thereof, and use thereof in medicines |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| RU2762893C2 (ru) | 2017-05-18 | 2021-12-23 | Цзянсу Хэнжуй Медсин Ко., Лтд. | Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли |
| CN109937200B (zh) | 2017-05-18 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃类衍生物游离碱的晶型及制备方法 |
| CN106977483A (zh) * | 2017-06-02 | 2017-07-25 | 遵义医学院 | 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法 |
| CA3082287C (en) | 2017-11-14 | 2023-02-28 | Pfizer Inc. | Ezh2 inhibitor combination therapies |
| HUE059536T2 (hu) | 2018-01-31 | 2022-11-28 | Mirati Therapeutics Inc | PRC2-inhibitorok |
| US11319302B2 (en) * | 2018-06-07 | 2022-05-03 | The Regents Of The University Of Michigan | PRC1 inhibitors and methods of treatment therewith |
| CN112399857A (zh) | 2018-07-09 | 2021-02-23 | 盲人庇护基金会 | Prc2亚单位的抑制治疗眼失调 |
| WO2020086857A1 (en) * | 2018-10-24 | 2020-04-30 | Vanderbilt University | Wdr5 inhibitors and modulators |
| CN111320582A (zh) * | 2018-12-17 | 2020-06-23 | 江苏恩华药业股份有限公司 | 一种类酰胺类衍生物及其中间体的制备方法 |
| KR102689665B1 (ko) * | 2019-02-19 | 2024-07-31 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
| US12421228B2 (en) | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| CN114269748A (zh) | 2019-06-05 | 2022-04-01 | 米拉蒂医疗股份有限公司 | 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物 |
| PE20230732A1 (es) | 2020-08-13 | 2023-05-03 | Hanmi Pharmaceutical Co Ltd | Derivados de dioxoloisoquinolinona novedosos y uso de los mismos |
| KR102386403B1 (ko) * | 2020-08-13 | 2022-04-15 | 한미약품 주식회사 | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 |
| WO2022179584A1 (zh) * | 2021-02-26 | 2022-09-01 | 南京药石科技股份有限公司 | 新型ezh2抑制剂及其用途 |
| EP4634152A1 (en) | 2022-12-15 | 2025-10-22 | Syngenta Crop Protection AG | Novel bicyclic-carboxamide compounds useful as pesticides |
| CN118978498B (zh) * | 2024-10-22 | 2025-04-01 | 浙江雅辰药物科技股份有限公司 | 一种5-羟甲基四氢呋喃-3-醇的制备方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3846412A (en) | 1971-03-18 | 1974-11-05 | Lepetit Spa | Dihydro-2-amino-isoquinolines and their derivatives |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| EP1940819A1 (en) | 2005-08-16 | 2008-07-09 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| WO2011103016A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| ES2528269T3 (es) | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| EP2566328B1 (en) | 2010-05-07 | 2015-03-04 | GlaxoSmithKline LLC | Indazoles |
| EP2566327B1 (en) | 2010-05-07 | 2017-03-29 | Glaxosmithkline LLC | Indoles |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| EP2627648A1 (en) | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2681216B1 (en) * | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TWI598336B (zh) * | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| CA2850570A1 (en) | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| JP6254169B2 (ja) | 2012-09-28 | 2017-12-27 | ファイザー・インク | ベンズアミドおよびヘテロベンズアミド化合物 |
| BR112015014752B1 (pt) | 2012-12-21 | 2022-07-05 | Plexxikon, Inc | Compostos e seus uso para modulação de cinase |
| HRP20182037T1 (hr) | 2012-12-21 | 2019-02-08 | Epizyme, Inc. | Inhibitori prmt5 i njihova uporaba |
| PE20151499A1 (es) | 2012-12-21 | 2015-10-29 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| SG11201503526UA (en) | 2012-12-21 | 2015-06-29 | Sanofi Sa | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
| FR3000059A1 (fr) | 2012-12-21 | 2014-06-27 | Saint Gobain Placo | Composition pour plaques de platre et produits obtenus |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| LT2935312T (lt) | 2012-12-21 | 2018-10-25 | F. Hoffmann-La Roche Ag | Peptidai, kaip oksitocino agonistai |
| EP3421482A1 (en) | 2012-12-21 | 2019-01-02 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| BR112016029612B1 (pt) | 2014-06-17 | 2021-01-19 | Pfizer Inc. | compostos de di-hidroisoquinolinona substituídos |
-
2013
- 2013-05-12 UA UAA201505087A patent/UA111305C2/uk unknown
- 2013-12-05 PL PL13817739T patent/PL2935238T3/pl unknown
- 2013-12-05 PT PT138177399T patent/PT2935238T/pt unknown
- 2013-12-05 CU CU2015000062A patent/CU24414B1/es unknown
- 2013-12-05 NZ NZ708801A patent/NZ708801A/en not_active IP Right Cessation
- 2013-12-05 LT LTEP17206218.4T patent/LT3339303T/lt unknown
- 2013-12-05 MY MYPI2020003405A patent/MY192259A/en unknown
- 2013-12-05 GE GEAP201313863A patent/GEP201706718B/en unknown
- 2013-12-05 MA MA38175A patent/MA38175B1/fr unknown
- 2013-12-05 DK DK17206218.4T patent/DK3339303T3/da active
- 2013-12-05 RS RS20200917A patent/RS60582B9/sr unknown
- 2013-12-05 BR BR112015014678-3A patent/BR112015014678B1/pt not_active IP Right Cessation
- 2013-12-05 ES ES17206218T patent/ES2808987T3/es active Active
- 2013-12-05 RS RS20180103A patent/RS56815B1/sr unknown
- 2013-12-05 PT PT172062184T patent/PT3339303T/pt unknown
- 2013-12-05 CR CR20200273A patent/CR20200273A/es unknown
- 2013-12-05 CN CN201380066782.2A patent/CN104870435B/zh not_active Expired - Fee Related
- 2013-12-05 HR HRP20180060TT patent/HRP20180060T1/hr unknown
- 2013-12-05 HU HUE17206218A patent/HUE050009T2/hu unknown
- 2013-12-05 PE PE2015001044A patent/PE20151090A1/es active IP Right Grant
- 2013-12-05 PL PL17206218T patent/PL3339303T3/pl unknown
- 2013-12-05 WO PCT/IB2013/060682 patent/WO2014097041A1/en not_active Ceased
- 2013-12-05 AU AU2013365908A patent/AU2013365908C1/en not_active Ceased
- 2013-12-05 MD MDA20150052A patent/MD4664C9/ro not_active IP Right Cessation
- 2013-12-05 SG SG11201504076XA patent/SG11201504076XA/en unknown
- 2013-12-05 MX MX2015008058A patent/MX2015008058A/es active IP Right Grant
- 2013-12-05 EP EP13817739.9A patent/EP2935238B1/en active Active
- 2013-12-05 MY MYPI2015701733A patent/MY176307A/en unknown
- 2013-12-05 DK DK13817739.9T patent/DK2935238T3/en active
- 2013-12-05 EP EP17206218.4A patent/EP3339303B9/en active Active
- 2013-12-05 CA CA2893339A patent/CA2893339C/en active Active
- 2013-12-05 HU HUE13817739A patent/HUE038238T2/hu unknown
- 2013-12-05 KR KR1020157019806A patent/KR101712441B1/ko not_active Expired - Fee Related
- 2013-12-05 ME MEP-2020-147A patent/ME03793B/me unknown
- 2013-12-05 AP AP2015008574A patent/AP2015008574A0/xx unknown
- 2013-12-05 JP JP2015548808A patent/JP5909308B2/ja active Active
- 2013-12-05 ES ES13817739.9T patent/ES2658974T3/es active Active
- 2013-12-05 SI SI201331756T patent/SI3339303T1/sl unknown
- 2013-12-05 TR TR2018/02791T patent/TR201802791T4/tr unknown
- 2013-12-05 LT LTEP13817739.9T patent/LT2935238T/lt unknown
- 2013-12-05 EA EA201590879A patent/EA028317B1/ru unknown
- 2013-12-05 SI SI201330958T patent/SI2935238T1/en unknown
- 2013-12-18 US US14/132,567 patent/US9040515B2/en active Active
- 2013-12-18 TW TW102146910A patent/TWI546293B/zh not_active IP Right Cessation
- 2013-12-19 AR ARP130104902A patent/AR094174A1/es not_active Application Discontinuation
- 2013-12-20 UY UY0001038712A patent/UY38712A/es not_active Application Discontinuation
- 2013-12-20 UY UY0001035225A patent/UY35225A/es not_active Application Discontinuation
-
2014
- 2014-02-28 NO NO14709442A patent/NO2961649T3/no unknown
-
2015
- 2015-03-09 US US14/642,274 patent/US20150175572A1/en not_active Abandoned
- 2015-05-26 CR CR20150279A patent/CR20150279A/es unknown
- 2015-06-16 PH PH12015501367A patent/PH12015501367B1/en unknown
- 2015-06-18 IL IL239520A patent/IL239520B/en active IP Right Grant
- 2015-06-18 CL CL2015001733A patent/CL2015001733A1/es unknown
- 2015-06-18 TN TNP2015000281A patent/TN2015000281A1/fr unknown
- 2015-06-19 DO DO2015000157A patent/DOP2015000157A/es unknown
- 2015-06-19 ZA ZA2015/04437A patent/ZA201504437B/en unknown
- 2015-06-19 GT GT201500190A patent/GT201500190A/es unknown
- 2015-06-19 MX MX2020002924A patent/MX2020002924A/es unknown
- 2015-07-21 EC ECIEPI201531579A patent/ECSP15031579A/es unknown
-
2017
- 2017-05-03 US US15/585,880 patent/US10246433B2/en active Active
-
2018
- 2018-02-05 CY CY20181100137T patent/CY1119883T1/el unknown
- 2018-09-05 ME MEP-2018-8A patent/ME02980B/me unknown
-
2020
- 2020-07-30 HR HRP20201194TT patent/HRP20201194T2/hr unknown
- 2020-08-11 CY CY20201100746T patent/CY1123237T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151090A1 (es) | Lactamas fusionadas de arilo y heteroarilo | |
| ECSP22091792A (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos | |
| PE20151023A1 (es) | Triazolopirazinas | |
| UY33883A (es) | Novedosos derivados heterocíclicos | |
| CL2016001733A1 (es) | Compuestos intermediarios para la preparación de compuestos derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer div. sol. 3415-12. | |
| CR20150370A (es) | Compuestos antivirales | |
| MX2017016995A (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| CR20140399A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| CU20170162A7 (es) | Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen | |
| UY36170A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| UY33199A (es) | 5-alquinil-pirimidinas. | |
| CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
| UY34318A (es) | ?derivados de isotiazolina útiles como compuestos insecticidas? | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| PE20150966A1 (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina | |
| MX2019003026A (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| UY36228A (es) | Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen | |
| PE20150707A1 (es) | Inhibidores de la beta-secretasa | |
| UY34754A (es) | ?mezcla para mejora del crecimiento de las plantas?. | |
| UY35785A (es) | Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1) | |
| CR20150148A (es) | Azaindolinas | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| UY33912A (es) | Derivados de oxima como agonistas de gpr119 | |
| ECSP12012110A (es) | 5-alquinil-pirimidinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |